Van Melle
Van Melle et al et al (2007) reported that (2007) reported that cardiac prognosis post-myocardial infarccardiac prognosis post-myocardial infarction was not improved by antidepressant tion was not improved by antidepressant treatment (MIND-IT trial). The SADHART treatment (MIND-IT trial). The SADHART and ENRICHD trials reported similar findand ENRICHD trials reported similar findings and Carney & Freedland (2007) , in ings and Carney & Freedland (2007) , in their commentary in the same issue, suggest their commentary in the same issue, suggest these negative findings are a result of insufthese negative findings are a result of insufficient statistical power in the trials. These ficient statistical power in the trials. These results are disappointing but perhaps they results are disappointing but perhaps they might have been anticipated. might have been anticipated.
There is strong evidence that indiviThere is strong evidence that individuals with depression show increased morduals with depression show increased morbidity and mortality from coronary heart bidity and mortality from coronary heart disease (Rugulies, 2002) but the mechandisease (Rugulies, 2002) but the mechanisms involved remain unclear. Individuals isms involved remain unclear. Individuals with a history of recurrent depression, with a history of recurrent depression, who are otherwise healthy, show increased who are otherwise healthy, show increased inflammation, platelet activation, endotheinflammation, platelet activation, endothelial dysfunction, and reduced heart rate lial dysfunction, and reduced heart rate variability and baroreceptor sensitivity. variability and baroreceptor sensitivity. However, with the exception of platelet However, with the exception of platelet function, which improves with selective function, which improves with selective serotonin reuptake inhibitors, these anomserotonin reuptake inhibitors, these anomalies are not corrected by antidepressant alies are not corrected by antidepressant treatment. Furthermore, endothelial functreatment. Furthermore, endothelial function and baroreceptor sensitivity, which tion and baroreceptor sensitivity, which can lead respectively to progression of the can lead respectively to progression of the atherosclerotic process and to sudden cardiatherosclerotic process and to sudden cardiac death, do not improve when depressive ac death, do not improve when depressive symptoms are in remission (Broadley symptoms are in remission (Broadley et al et al, , 2006) . Thus there is no evidence that 2006). Thus there is no evidence that treatment of depressive symptoms posttreatment of depressive symptoms postmyocardial infarction corrects these undermyocardial infarction corrects these underlying pathological processes and, if it does lying pathological processes and, if it does not, cardiac outcomes disclosed by clinical not, cardiac outcomes disclosed by clinical trials are unlikely to show improvement trials are unlikely to show improvement irrespective of their statistical power. By irrespective of their statistical power. By analogy, although hyperglycaemia characanalogy, although hyperglycaemia characterises diabetes, tight glucose control alone terises diabetes, tight glucose control alone has only a modest impact on cardiovascular has only a modest impact on cardiovascular events. Similarly, depressive illness is charevents. Similarly, depressive illness is characterised by acute episodes of depression, acterised by acute episodes of depression, but other systemic abnormalities are prebut other systemic abnormalities are present and persist between acute depressive sent and persist between acute depressive episodes. Accordingly, it may be unreasonepisodes. Accordingly, it may be unreasonable to believe that treatments assessed by able to believe that treatments assessed by their influence on the affective state alone their influence on the affective state alone will reduce cardiovascular events. will reduce cardiovascular events.
Although it is important to alleviate the Although it is important to alleviate the suffering associated with developing desuffering associated with developing depression post-myocardial infarction and pression post-myocardial infarction and improve prognosis by addressing the secimprove prognosis by addressing the secondary effects of depression (e.g. reduced ondary effects of depression (e.g. reduced adherence to treatment and poor health adherence to treatment and poor health behaviours), treatment needs to be aimed behaviours), treatment needs to be aimed at earlier stages of the disorder. Atheroat earlier stages of the disorder. Atherosclerosis begins in childhood and becomes sclerosis begins in childhood and becomes manifest much later in life, with myocardial manifest much later in life, with myocardial infarction as a very late presentation. Simiinfarction as a very late presentation. Similarly, depression is a lifelong disorder with larly, depression is a lifelong disorder with onset in early adulthood. It should be noted onset in early adulthood. It should be noted that currently depression is not even that currently depression is not even included in cardiovascular risk tables and included in cardiovascular risk tables and that individuals with depression might that individuals with depression might benefit from introduction of statins, or benefit from introduction of statins, or other preventative measures. other preventative measures.
We agree with Carney & Freedland We agree with Carney & Freedland (2007) that treatments for depression might (2007) that treatments for depression might alter the risk of cardiac events via pathways alter the risk of cardiac events via pathways that are unrelated to their effects on depresthat are unrelated to their effects on depression. However, if the focus of research were sion. However, if the focus of research were shifted to the study of earlier stages of shifted to the study of earlier stages of coronary heart disease in people with coronary heart disease in people with depression, this could be clarified by monidepression, this could be clarified by monitoring earlier indices of heart disease in toring earlier indices of heart disease in relation to treatment of depression. It is relation to treatment of depression. It is also recognised that mechanisms for also recognised that mechanisms for associations between depression and onset associations between depression and onset of heart disease may differ from those of heart disease may differ from those between depression and progression of between depression and progression of coronary heart disease post-myocardial incoronary heart disease post-myocardial infarction. These pathways need to be better farction. These pathways need to be better understood and present evidence suggests understood and present evidence suggests that survival times following myocardial that survival times following myocardial infarction could be improved by developing infarction could be improved by developing treatments for depression that also target treatments for depression that also target the underlying cardiovascular abnormalthe underlying cardiovascular abnormalities and by augmenting these by preities and by augmenting these by preventative programmes for coronary heart ventative programmes for coronary heart disease in individuals with mood disorders. disease in individuals with mood disorders.
Coronary heart disease and depression Coronary heart disease and depression are two major public health problems and are two major public health problems and it is of concern that reports of treatments it is of concern that reports of treatments for depression failing to enhance survival for depression failing to enhance survival post-myocardial infarction may result in post-myocardial infarction may result in less interest in studying the links between less interest in studying the links between them. them. (2007) present findings from their randomised controlled trial exfrom their randomised controlled trial examining the effects of antidepressant treatamining the effects of antidepressant treatment for depression following myocardial ment for depression following myocardial infarction. I would like to comment on infarction. I would like to comment on the design of the study. Patients were allothe design of the study. Patients were allocated to two arms: antidepressant treatcated to two arms: antidepressant treatment and care as usual. Patients in the ment and care as usual. Patients in the care-as-usual arm were not told about their care-as-usual arm were not told about their research diagnosis of depression. The research diagnosis of depression. The authors quote Zelen (1979) , thus implying authors quote Zelen (1979) , thus implying that they are following the research design that they are following the research design he proposed. However, Zelen's method he proposed. However, Zelen's method seems best suited to trials where there is a seems best suited to trials where there is a 'gold standard' control treatment available 'gold standard' control treatment available and the trial is attempting to evaluate a and the trial is attempting to evaluate a new experimental treatment (Zelen, 1979) . new experimental treatment (Zelen, 1979) . In this design, the ethical concerns are mainly In this design, the ethical concerns are mainly about randomising before consent is sought. about randomising before consent is sought. It must be pointed out that after randomisIt must be pointed out that after randomisation, consent is sought from patients in ation, consent is sought from patients in the experimental arm. If they decline, they the experimental arm. If they decline, they are moved to the 'gold standard' arm (Torare moved to the 'gold standard' arm (Torgerson, 2001 
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